Avidity Biosciences (RNA) Competitors $30.84 +0.01 (+0.03%) Closing price 03/21/2025 04:00 PM EasternExtended Trading$30.87 +0.03 (+0.10%) As of 03/21/2025 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock RNA vs. SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, and QGENShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Summit Therapeutics Intra-Cellular Therapies Genmab A/S Moderna Viatris Dr. Reddy's Laboratories Ascendis Pharma A/S Sarepta Therapeutics Vaxcyte Qiagen Summit Therapeutics (NASDAQ:SMMT) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation. Do insiders and institutionals hold more shares of SMMT or RNA? 4.6% of Summit Therapeutics shares are held by institutional investors. 88.3% of Summit Therapeutics shares are held by company insiders. Comparatively, 3.7% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, SMMT or RNA? Summit Therapeutics has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Is SMMT or RNA more profitable? Summit Therapeutics has a net margin of 0.00% compared to Avidity Biosciences' net margin of -2,772.45%. Avidity Biosciences' return on equity of -27.66% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Summit TherapeuticsN/A -85.42% -52.66% Avidity Biosciences -2,772.45%-27.66%-24.56% Does the MarketBeat Community prefer SMMT or RNA? Summit Therapeutics received 140 more outperform votes than Avidity Biosciences when rated by MarketBeat users. However, 69.01% of users gave Avidity Biosciences an outperform vote while only 58.48% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformSummit TherapeuticsOutperform Votes30758.48% Underperform Votes21841.52% Avidity BiosciencesOutperform Votes16769.01% Underperform Votes7530.99% Which has stronger valuation and earnings, SMMT or RNA? Avidity Biosciences has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSummit Therapeutics$700K20,813.11-$614.93M-$0.31-63.71Avidity Biosciences$10.90M340.22-$212.22M-$2.89-10.67 Do analysts rate SMMT or RNA? Summit Therapeutics currently has a consensus price target of $34.11, suggesting a potential upside of 72.71%. Avidity Biosciences has a consensus price target of $66.69, suggesting a potential upside of 116.25%. Given Avidity Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Avidity Biosciences is more favorable than Summit Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SMMT or RNA? In the previous week, Avidity Biosciences had 18 more articles in the media than Summit Therapeutics. MarketBeat recorded 30 mentions for Avidity Biosciences and 12 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.82 beat Avidity Biosciences' score of 0.38 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 8 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAvidity Biosciences beats Summit Therapeutics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.71B$7.13B$5.73B$8.13BDividend YieldN/A2.72%4.39%4.03%P/E Ratio-10.717.3524.7419.07Price / Sales340.22236.88398.9891.58Price / CashN/A65.6738.1634.64Price / Book4.566.737.104.43Net Income-$212.22M$142.90M$3.20B$247.36M7 Day Performance-0.87%3.14%1.98%1.98%1 Month Performance-0.90%-1.51%3.59%-6.10%1 Year Performance30.13%-5.14%14.49%3.48% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences1.8134 of 5 stars$30.84+0.0%$66.69+116.3%+30.1%$3.71B$10.90M-10.71190Insider TradeSMMTSummit Therapeutics2.5275 of 5 stars$20.13-3.2%$34.11+69.5%+486.1%$14.85B$700,000.00-71.89110Analyst ForecastITCIIntra-Cellular Therapies3.5685 of 5 stars$131.45+0.1%$106.08-19.3%+90.7%$13.98B$680.50M-151.09560Analyst ForecastPositive NewsGMABGenmab A/S4.0576 of 5 stars$20.80+1.4%$41.33+98.7%-34.0%$13.76B$21.53B11.952,204Analyst RevisionMRNAModerna4.0898 of 5 stars$34.71+0.3%$59.60+71.7%-69.0%$13.39B$3.20B-3.743,900Analyst ForecastVTRSViatris1.9608 of 5 stars$9.25+1.6%$10.50+13.5%-22.7%$11.04B$14.74B-12.5037,000News CoverageRDYDr. Reddy's Laboratories2.0725 of 5 stars$13.23+4.3%$17.00+28.5%-6.6%$11.04B$311.31B21.0624,800Analyst RevisionNews CoverageGap UpASNDAscendis Pharma A/S1.8398 of 5 stars$168.84+10.4%$202.36+19.9%+14.5%$10.25B$363.64M-23.781,017Analyst ForecastHigh Trading VolumeSRPTSarepta Therapeutics4.5488 of 5 stars$101.35+4.3%$170.41+68.1%-41.9%$9.83B$1.90B81.081,314Analyst ForecastOptions VolumeNews CoveragePCVXVaxcyte2.3352 of 5 stars$75.23+1.2%$147.50+96.1%+11.1%$9.69BN/A-16.35160Positive NewsQGENQiagen4.0092 of 5 stars$39.85+0.9%$47.71+19.7%-6.9%$8.84B$1.98B110.955,967Short Interest ↓ Remove Ads Related Companies and Tools Related Companies Summit Therapeutics Competitors Intra-Cellular Therapies Competitors Genmab A/S Competitors Moderna Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Sarepta Therapeutics Competitors Vaxcyte Competitors Qiagen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 3/23/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
